Neurocrine/$NBIX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Neurocrine
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
Ticker
$NBIX
Sector
Primary listing
Employees
2,000
Headquarters
Website
Neurocrine Metrics
BasicAdvanced
$17bn
24.45
$6.82
0.39
-
Price and volume
Market cap
$17bn
Beta
0.39
52-week high
$186.12
52-week low
$122.14
Average daily volume
1.3m
Financial strength
Current ratio
1.872
Quick ratio
1.46
Long term debt to equity
10.878
Total debt to equity
10.878
Interest coverage (TTM)
301.62%
Profitability
EBITDA (TTM)
904.5
Gross margin (TTM)
64.63%
Net profit margin (TTM)
20.91%
Operating margin (TTM)
25.93%
Effective tax rate (TTM)
24.96%
Revenue per employee (TTM)
$1,690,000
Management effectiveness
Return on assets (TTM)
11.82%
Return on equity (TTM)
22.09%
Valuation
Price to earnings (TTM)
24.447
Price to revenue (TTM)
4.956
Price to book
4.56
Price to tangible book (TTM)
17.4
Growth
Revenue change (TTM)
34.42%
Earnings per share change (TTM)
101.21%
3-year revenue growth (CAGR)
26.34%
10-year revenue growth (CAGR)
71.87%
3-year earnings per share growth (CAGR)
57.74%
10-year earnings per share growth (CAGR)
16.93%
What the Analysts think about Neurocrine
Analyst ratings (Buy, Hold, Sell) for Neurocrine stock.
Neurocrine Financial Performance
Revenues and expenses
Neurocrine Earnings Performance
Company profitability
Neurocrine News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.